- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (68)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (28)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (236)
- Breast Cancer (714)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (158)
- Colon Cancer (166)
- Colorectal Cancer (108)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (2)
- Kidney Cancer (124)
- Leukemia (352)
- Liver Cancer (50)
- Lung Cancer (290)
- Lymphoma (286)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (102)
- Myelodysplastic Syndrome (64)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (102)
- Ovarian Cancer (176)
- Pancreatic Cancer (172)
- Parathyroid Disease (2)
- Penile Cancer (16)
- Pituitary Tumor (6)
- Prostate Cancer (148)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (234)
- Skin Cancer (296)
- Skull Base Tumors (54)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (92)
- Thymoma (6)
- Thyroid Cancer (98)
- Tonsil Cancer (32)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (8)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (624)
- Complementary Integrative Medicine (22)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (222)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (122)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (116)
- Molecular Diagnostics (8)
- Pain Management (64)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (874)
- Research (402)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (600)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (402)
- Survivorship (324)
- Symptoms (180)
- Treatment (1762)
Hortobagyi honored by ASCO for his work against breast cancer
2 minute read | Published June 03, 2019
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on June 03, 2019
Improvements in breast cancer treatment over the past five decades have reduced the mortality rate of women with the disease by 40 percent and improved the quality of life of patients, MD Anderson expert Gabriel Hortobagyi, M.D., professor of Breast Medical Oncology noted in a lecture at the 2019 American Society of Clinical Oncology Annual Meeting.
Hortobagyi spoke as this year’s winner of the David A. Karnofsky Memorial Award, bestowed annually by ASCO to recognize an oncologist who has made outstanding contributions to cancer research, diagnosis, and/or treatment.
In announcing the honor earlier this year, ASCO noted Hortobagyi’s “career, which spans more than 40 years, has focused on clinical and translational research, as well as teaching and mentoring the next generation of scientists and academic leadership. He is one of the world's leading authorities on the management of breast cancer.”
Hortobagyi, who also holds the Nellie B. Connally Chair in Breast Cancer, and directs the Susan G. Komen Interdisciplinary Breast Fellowship Program at MD Anderson, spoke during the opening session of the meeting Saturday.
Advances in scientific understanding of breast cancer, breast cancer diagnosis, and expansion of treatment options beyond surgery and radiation to include targeted therapies have all played a role, he noted. The genetic and molecular heterogeneity of breast cancer remains a challenge being addressed by research and clinical trials.
Hortobagyi has authored more than 1,000 scientific articles and is credited with leading pioneering advances in treating the disease, including combination chemotherapies for inoperable tumors and multidisciplinary care for patients at all disease stages.
His many innovative contributions to the field include:
- An early study that gave chemotherapy before surgery to breast cancer patients with locally advanced tumors showed most large tumors could be reduced by at least 50% with the preoperative chemotherapy and then removed surgically.
- Led the clinical development of anthracyclines and taxanes as breast cancer treatment.
- More recently, he has focused his research on combining endocrine therapy with targeted agents, leading development of the mTOR inhibitor everolimus and the clinical development of CDK4/6 inhibitors, including ribociclib.
Hortobagyi developed, implemented, and chaired the MONALEESA-2 phase III trial, assessing the efficacy and safety of ribociclib in combination with letrozole in patients with hormone receptor-positive metastatic breast cancer. Overall survival data on that trial was highlighted Saturday morning at ASCO.
Topics
Breast Cancer